Now, one type of weight-loss medication is proving helpful with another health issue. In a study published Feb. 12 in JAMA ...

Eli Lilly and Company (NYSE: LLY) is one of two pharmaceutical stocks behind the weight loss drug craze that has impacted the ...

After pre-announcing that its full-year revenue would come in below its original guidance, Eli Lilly (NYSE: LLY) announced ...

U.S. investors and large pharmaceutical companies are increasingly doing deals in China as the country’s biopharma sector ...

For years, people taking Ozempic or other drugs in the same class for diabetes and weight loss have noticed the medicines don ...

On Super Bowl Sunday, many tuning into the big game saw a controversial ad from the telehealth company Hims & Hers. The ...

Shortly after Hims & Hers aired its controversial Super Bowl ad promoting its compounded GLP-1 offerings, Novo Nordisk has ...

The next FDA Commissioner could solve two big problems with one powerful policy: encourage independent testing of both ...

The popular weight-loss drugs known as GLP-1 receptor agonists, which were originally meant to treat diabetes, surged in ...

Ozempic and Wegovy maker Novo Nordisk placed a print ad responding to the Super Bowl spot from competitor Hims & Hers.

Hims & Hers offers a copycat of the blockbuster weight-loss drug at a fraction of the cost. But it might be a short-lived ...

GLP-1 drugs like Ozempic and Wegovy revolutionized weight loss, but their high cost keeps them out of reach for most ...